Mithra and Orifarm Sign LSA for Vaginal Contraception Ring in Denmark

  • Mithra grants exclusive license for vaginal contraception ring to Orifarm for commercialization in Denmark/li>
  • Agreement follows MyringTM licenses closed with Mayne Pharma, Gynial, Adamed and Alvogen for the US, Austria, the Czech Republic and Russia, respectively
  • Vaginal ring shall be manufactured at Mithra CDMO

Liège, Belgium, 21 June 2018 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces an exclusive license and supply agreement (LSA) with Orifarm for the commercialization in Denmark of Mithra’s contraceptive vaginal ring product candidate made of ethylene vinyl acetate copolymers (EVA).